Stem cell therapy for Alzheimer's disease

doi:10.4252/wjsc.v12.i8.787

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 12, Issue 8

This Article

Academic Content and Language Evaluation of This Article

CrossCheck and Google Search of This Article

Academic Rules and Norms of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

Total Article Views (18285)

All Articles published online

The chart showing PDF series, WORD series, HTML series, Tables (1-1) series.

Item

Count

PDF

1149

WORD

259

HTML

14227

Tables (1-1)

409

Sum=16044

Publishing Process of This Article

The chart showing Browse series, Download series.

Item

Count

Browse

754

Download

1487

Sum=2241

Aug 26, 2020 (publication date) through Nov 3, 2024

Times Cited of This Article

Times Cited (90)

Journal Information of This Article

Publication Name

World Journal of Stem Cells

ISSN

1948-0210

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Review

World J Stem Cells. Aug 26, 2020; 12(8): 787-802
Published online Aug 26, 2020. doi: 10.4252/wjsc.v12.i8.787

Table 1 Completed clinical trial trials of stem cells in patients with Alzheimer’s disease

Study name (study date)	Current state	Length (phase)	Site	Subjects (age)	Design	Stem cell	Route (n)	Dosage (participants)	n¹	Outcome measures
Study name (study date)	Current state	Length (phase)	Site	Subjects (age)	Design	Stem cell	Route (n)	Dosage (participants)	n¹	Primary	Secondary
NCT03117738 (4/2017-9/2019)	Active, NR	32 wk (I/II)	United States	AD (> 50)	PBO-control, Double-blind	AD-MSC	IV (9)	NA	21	ADAS-cog	MMSE, CDR-SB, NPI, GDS, ADL, biomarkers (MRI, Aβ, etc.)
NCT04040348 (4/2019-9/2021)	Recruiting	65 wk (I)	United States	AD (50-85)	Open label	H-MSC	IV (NA)	1 × 10⁸ (5), 2 × 10⁸ (5)	10	AE number	ADAS-cog, MMSE, GDS, ADL, NPI, diverse biomarkers
NCT02600130 (4/2019-9/2021)	Active, NR	65 wk (II)	United States	AD (50-80)	PBO-control, Double-blind	L-MSC	IV (1)	2 × 10⁷ (10), 1 × 10⁸ (10), PBO (5)	25	AE number	ADAS-cog, ADL, biomarkers (CSF, Aβ)
NCT02672306 (10/2017-10/2019)	Active, NR	36 wk (I/II)	China	AD (50-85)	PBO-control, Double-blind	HUC-MSC	IV (8)	0.5 × 10⁶/kg (NA), PBO (NA)	16	ADAS-cog	ADAS-cog, CIBIC, CIBIC plus, MMSE, ADL, NPI biomarkers (plasma Aβ, etc.)
NCT03724136 (10/2018-10/2022)	Recruiting	12 mo	United States	AD+ other neurological disease (> 18)	Open label, Three groups	B-MSC	IV (NA)	NA	100	MMSE, ASQ-SE	Activities of daily living
NCT01547689 (2012.3-2016.12)	Unknown status	10 wk (I/II)	China	AD (50-85)	Open label, Single-center, Self-control	HUC-MSC	IV (8)	0.5 × 10⁶/kg	30	AE number	ADAS-cog, MMSE, CIBIC, ADL, NPI biomarkers (Aβ, tau, etc.)

¹Number of total participants. Aβ: Amyloid-beta; AD: Dementia due to Alzheimer’s disease; ADAS-Cog: Alzheimer’s Disease Assessment Scale-Cognitive Subscale; AE: Adverse events; NPI: Neuropsychiatric Inventory; CSF: Cerebrospinal fluid; AD-MSC: Autologous adipose tissue-derived mesenchymal stem cells; H-MSC: Human mesenchymal stem cells; L-MSC: Leukemia mesenchymal stem cells; B-MSC: Bone marrow mesenchymal stem cells; HUC-MSC: Human umbilical cord blood-derived mesenchymal stem cells; ADL: Activities of daily living; NA: Not available; CDR-SB: Clinical Dementia Rating-Sum of the Boxes scale; GDS: Geriatric Depression Scale; MMSE: Minimum Mental State Examination; CIDIC: Composite International Diagnostic Interview Core; PBO: Placebo; IV: Intravenous; ASQ-SE: Ages and stages questionnaires-social-emotional.

Citation: Liu XY, Yang LP, Zhao L. Stem cell therapy for Alzheimer's disease. World J Stem Cells 2020; 12(8): 787-802
URL: https://www.wjgnet.com/1948-0210/full/v12/i8/787.htm
DOI: https://dx.doi.org/10.4252/wjsc.v12.i8.787